Kairos Pharma Ltd. (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company’s work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos’ focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.
The company’s lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
Kairos Pharma's recognition in the 2026 awards underscores the importance of its research in drug resistance, a major challenge in oncology. Drug resistance often limits the long-term efficacy of cancer treatments, leading to disease progression and relapse. By targeting CD105, Kairos aims to overcome this resistance, potentially offering new hope for patients with cancers that no longer respond to standard therapies. The award also validates the company's approach using structural biology to develop therapeutics that can be combined with existing treatments to improve outcomes.
For more details, visit the full press release at https://ibn.fm/WuBOf. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
Kairos Pharma Ltd., based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's focus on drug resistance development has the potential to impact a broad range of cancer types, making this award a significant milestone in its mission to extend the effectiveness of existing therapies.
